Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus chemotherapy as neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma
ChiCTR2300079277Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Harbin Medical University Cancer Hospital. Primary endpoints: pathological complete response rate and overall survival. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2300079277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300079277.